Kuzmanovic, MilosJurisic, Vladimir2015-12-312015-12-312012-08Kuzmanovic Milos, Jurisic Vladimir. Rituximab for Treatment of Autoimmune Hemolytic Anemia. Indian Pediatrics. 2012 August; 49(8): 672-674.http://imsear.searo.who.int/handle/123456789/169436We report the successful use of rituximab as single treatment modality in a five-month-old boy with fulminant warm autoantibody autoimmune hemolytic anemia, resistant to standard treatment. On admission, laboratory tests showed a profound anemia with a hemoglobin of 2.6 g/dL. Indirect and direct antiglobulin tests were strongly positive, and nonspecific IgG autoantibodies were detected. Two days of intravenous corticosteroids (methylprednisolone 4mg/kg) and immunoglobulins (1g/kg) did not halt the hemolysis and the infant was severely transfusion-dependent. Rituximab 375mg/sq m weekly was given for 4 weeks, the hepatosplenomegaly gradually regressed, the lymphocytes normalized and he is free from hemolysis two years after treatment.enAutoimmune hemolytic anemiaRituximabArticle